Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Jonathan R. Dry"'
Autor:
Orsolya Papp, Viktória Jordán, Szabolcs Hetey, Róbert Balázs, Valér Kaszás, Árpád Bartha, Nóra N. Ordasi, Sebestyén Kamp, Bálint Farkas, Jerome Mettetal, Jonathan R. Dry, Duncan Young, Ben Sidders, Krishna C. Bulusu, Daniel V. Veres
Publikováno v:
npj Systems Biology and Applications, Vol 10, Iss 1, Pp 1-15 (2024)
Abstract Combination therapy is well established as a key intervention strategy for cancer treatment, with the potential to overcome monotherapy resistance and deliver a more durable efficacy. However, given the scale of unexplored potential target s
Externí odkaz:
https://doaj.org/article/e4b72d20225b452aa4515315182adc6b
Autor:
Sebastijan Hobor, Maise Al Bakir, Crispin T. Hiley, Marcin Skrzypski, Alexander M. Frankell, Bjorn Bakker, Thomas B. K. Watkins, Aleksandra Markovets, Jonathan R. Dry, Andrew P. Brown, Jasper van der Aart, Hilda van den Bos, Diana Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H. Rabinowitz, Laila Ait Hassou, Saskia Litière, D. Lucas Kerr, Lisa Tan, Gavin Kelly, David A. Moore, Matthew J. Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R. M. Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M. Blakely, Elza C. de Bruin, Floris Foijer, Karen H. Vousden, Trever G. Bivona, TRACERx consortium, Robert E. Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here
Externí odkaz:
https://doaj.org/article/a58c4b29e1d8491b8078212067633916
Autor:
Orsolya Papp, Viktória Jordán, Szabolcs Hetey, Róbert Balázs, Valér Kaszás, Árpád Bartha, Nóra N. Ordasi, Sebestyén Kamp, Bálint Farkas, Jerome Mettetal, Jonathan R. Dry, Duncan Young, Ben Sidders, Krishna C. Bulusu, Daniel V. Veres
Publikováno v:
npj Systems Biology and Applications, Vol 10, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/b62fb2263bd9476cac36ae58196a22af
Autor:
Steven W. Criscione, Matthew J. Martin, Derek B. Oien, Aparna Gorthi, Ricardo J. Miragaia, Jingwen Zhang, Huawei Chen, Daniel L. Karl, Kerrin Mendler, Aleksandra Markovets, Sladjana Gagrica, Oona Delpuech, Jonathan R. Dry, Michael Grondine, Maureen M. Hattersley, Jelena Urosevic, Nicolas Floc’h, Lisa Drew, Yi Yao, Paul D. Smith
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-13 (2022)
Abstract Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR-TKI sensitizing or EGFR T790M resistance mutations. While patien
Externí odkaz:
https://doaj.org/article/d7852854a3ba43459578c3fb424140e2
Autor:
Benjamin D. Leibowitz, Bonnie V. Dougherty, Joshua S. K. Bell, Joshuah Kapilivsky, Jackson Michuda, Andrew J. Sedgewick, Wesley A. Munson, Tushar A. Chandra, Jonathan R. Dry, Nike Beaubier, Catherine Igartua, Timothy Taxter
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-17 (2022)
Abstract Background With the introduction of DNA-damaging therapies into standard of care cancer treatment, there is a growing need for predictive diagnostics assessing homologous recombination deficiency (HRD) status across tumor types. Following th
Externí odkaz:
https://doaj.org/article/dabd382b971d4f07ac2e0b21a3f9c4c3
Autor:
Anna Gogleva, Dimitris Polychronopoulos, Matthias Pfeifer, Vladimir Poroshin, Michaël Ughetto, Matthew J. Martin, Hannah Thorpe, Aurelie Bornot, Paul D. Smith, Ben Sidders, Jonathan R. Dry, Miika Ahdesmäki, Ultan McDermott, Eliseo Papa, Krishna C. Bulusu
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Resistance to EGFR inhibitors presents a major obstacle in treating non-small cell lung cancer. Here, the authors develop a recommender system ranking genes based on trade-offs between diverse types of evidence linking them to potential mechanisms of
Externí odkaz:
https://doaj.org/article/5696d9d8b857488d965cb75a14d75b2a
Autor:
Zhongwu Lai, Matthew Brosnan, Ethan S. Sokol, Mingchao Xie, Jonathan R. Dry, Elizabeth A. Harrington, J. Carl Barrett, Darren Hodgson
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background DNA repair deficiencies are characteristic of cancer and homologous recombination deficiency (HRD) is the most common. HRD sensitizes tumour cells to PARP inhibitors so it is important to understand the landscape of HRD across dif
Externí odkaz:
https://doaj.org/article/a8395d2b2b2345ee8ea9e874e657f84c
Autor:
Brian M. Larsen, Madhavi Kannan, Lee F. Langer, Benjamin D. Leibowitz, Aicha Bentaieb, Andrea Cancino, Igor Dolgalev, Bridgette E. Drummond, Jonathan R. Dry, Chi-Sing Ho, Gaurav Khullar, Benjamin A. Krantz, Brandon Mapes, Kelly E. McKinnon, Jessica Metti, Jason F. Perera, Tim A. Rand, Veronica Sanchez-Freire, Jenna M. Shaxted, Michelle M. Stein, Michael A. Streit, Yi-Hung Carol Tan, Yilin Zhang, Ende Zhao, Jagadish Venkataraman, Martin C. Stumpe, Jeffrey A. Borgia, Ashiq Masood, Daniel V.T. Catenacci, Jeremy V. Mathews, Demirkan B. Gursel, Jian-Jun Wei, Theodore H. Welling, Diane M. Simeone, Kevin P. White, Aly A. Khan, Catherine Igartua, Ameen A. Salahudeen
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109429- (2021)
Summary: Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a lack of s
Externí odkaz:
https://doaj.org/article/9e05120e2cf8481abf4978520140395c
Autor:
Matthew J. Sale, Emma Minihane, Noel R. Monks, Rebecca Gilley, Frances M. Richards, Kevin P. Schifferli, Courtney L. Andersen, Emma J. Davies, Mario Aladren Vicente, Eiko Ozono, Aleksandra Markovets, Jonathan R. Dry, Lisa Drew, Vikki Flemington, Theresa Proia, Duncan I. Jodrell, Paul D. Smith, Simon J. Cook
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-19 (2019)
BRAF or MEK1/2 inhibitors are cytostatic in melanoma and the surviving cells develop drug resistance. This study shows that the pro-survival pool is biased towards MCL1 in melanoma so that BRAF or MEK1/2 inhibitors are synthetic lethal with the MCL1
Externí odkaz:
https://doaj.org/article/03dfbb8e162440b8bfec0b14545e606c
Autor:
Michael P. Menden, Dennis Wang, Mike J. Mason, Bence Szalai, Krishna C. Bulusu, Yuanfang Guan, Thomas Yu, Jaewoo Kang, Minji Jeon, Russ Wolfinger, Tin Nguyen, Mikhail Zaslavskiy, AstraZeneca-Sanger Drug Combination DREAM Consortium, In Sock Jang, Zara Ghazoui, Mehmet Eren Ahsen, Robert Vogel, Elias Chaibub Neto, Thea Norman, Eric K. Y. Tang, Mathew J. Garnett, Giovanni Y. Di Veroli, Stephen Fawell, Gustavo Stolovitzky, Justin Guinney, Jonathan R. Dry, Julio Saez-Rodriguez
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-17 (2019)
Resistance to first line treatment is a major hurdle in cancer treatment, that can be overcome with drug combinations. Here, the authors provide a large drug combination screen across cancer cell lines to benchmark crowdsourced methods and to computa
Externí odkaz:
https://doaj.org/article/3c1d1aa1326641e8904a43901d3324f8